All In Biotech

Drug Trial Radar · NCT05032040

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Jul 21, 2022

Primary completion

Oct 15, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Xencor, Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Conditions

  • Ovarian Cancer
  • Clear Cell Carcinoma
  • Endometrial Cancer
  • Cervical Carcinoma
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

  • vudalimabBiological

    Monoclonal bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohortsTime frame: 12 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - NAHOA

    Prescott, Arizona

  • UCSD Moores Cancer Center

    La Jolla, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • Kaiser Permanente Medical Group

    Riverside, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada-Southern Hills

    Las Vegas, Nevada

  • NYU Langone Health

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • Texas Oncology - Central South

    Austin, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.